Sleep and breathing in idiopathic pulmonary fibrosis.
The outcome of patients with idiopathic pulmonary fibrosis (IPF), which represents the most common type of idiopathic pulmonary pneumonias, is poor. Breathlessness and coughing are usually progressive and about 50% of he patients die within 3 years after diagnosis. The effect of medical treatment in terms of survival is disappointing. Most of the currently available studies only focus on daytime diagnostics and therapy. The role of sleep quality and sleep disordered breathing in IPF is only investigated in a small number of papers, which can be summarized as follows: sleep fragmentation in IPF is very common. The reasons might be coughing, nocturnal oxygen desaturations, and increased respiratory drive. Sleep disorders in IPF have a profound impact on the quality of life. Oxygen desaturations often appear during sleep and can be predicted by the PaO(2) during wakefulness. There are no evidence-based recommendations concerning the indication for oxygen therapy and non-invasive ventilation during sleep in IPF. Obstructive sleep apnea (OSA) has no increased incidence with the exception of the IPF patients with an increased body mass index. If, however, OSA is present in IPF oxygen desaturations are more profound. The therapy of sleep disorders and sleep disordered breathing in IPF is individual. But in the absence of an effective treatment of IPF, optimization of sleep and life quality by the treatment of sleep disorders seems to be a primary goal. Further studies are needed to determine special sleep-related treatment effects.
Rasche
K
K
Lungcenter, St. Antonius Hospital, Wuppertal, Germany. rasche@antonius.de
Orth
M
M
D006801:Humans; D054990:Idiopathic Pulmonary Fibrosis / Q000150:complications* / Q000503:physiopathology* / Q000628:therapy; D011788:Quality of Life; D012119:Respiration; D015656:Respiratory Mechanics / Q000502:physiology; D012890:Sleep; D012891:Sleep Apnea Syndromes / Q000209:etiology* / Q000503:physiopathology* / Q000628:therapy